These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32052245)

  • 1. Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.
    Fu X; Lou H; Chen F; Gao X; Lin Z
    Clin Exp Med; 2020 May; 20(2):241-248. PubMed ID: 32052245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment.
    Zhao XA; Wang J; Liu J; Chen G; Yan X; Jia B; Yang Y; Liu Y; Gu D; Zhang Z; Xiang X; Huang R; Wu C
    Antiviral Res; 2021 Sep; 193():105146. PubMed ID: 34314774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B.
    Shen S; Wong GL; Kuang Z; van Campenhout MJH; Fan R; Wong VW; Yip TC; Chi H; Liang X; Hu X; Lin W; Wu Y; Liu X; Boonstra A; Hou J; Sun J; Chan HL
    J Med Virol; 2020 Aug; 92(8):1206-1213. PubMed ID: 31724212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs.
    Cai S; Li Z; Yu T; Xia M; Peng J
    Infect Drug Resist; 2018; 11():469-477. PubMed ID: 29662321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment.
    Yang J; Yan D; Guo R; Chen J; Li Y; Fan J; Fu X; Yao X; Diao H; Li L
    Medicine (Baltimore); 2017 Mar; 96(10):e6242. PubMed ID: 28272219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H; Wang C; Zhang Y; Wei S; Li X; Zhang Z
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
    Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
    Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
    J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Children With a Normal Alanine Aminotransferase Level.
    Chen HS; Wu JF; Su TH; Chen HL; Hsu HY; Xia NS; Chen PJ; Chang MH
    Hepatology; 2019 Dec; 70(6):1903-1912. PubMed ID: 31121067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy.
    Yuen MF; Yuan HJ; Hui CK; Wong DK; Wong WM; Chan AO; Wong BC; Lai CL
    Gut; 2003 Mar; 52(3):416-9. PubMed ID: 12584226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
    Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
    J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study.
    Fung J; Lai CL; Wong DK; Seto WK; Hung I; Yuen MF
    J Viral Hepat; 2011 Jul; 18(7):e200-5. PubMed ID: 21692933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.